Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $12 to $15.
B. Riley Securities analyst Anderson Schock initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price ...
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $11.
Keybanc analyst Paul Knight upgrades Exagen (NASDAQ:XGN) from Sector Weight to Overweight and maintains the price target fro...
Exagen (NASDAQ:XGN) sees FY2025 sales of $65.000 million-$70.000 million vs $65.515 million analyst estimate.
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28...
